Last reviewed · How we verify
CMV Retinitis in AIDS Patients
Approved treatments
- Valcyte · Cheplapharm
Valcyte works by inhibiting the replication of cytomegalovirus DNA through its action as a nucleoside analog DNA polymerase inhibitor. - Vistide · Gilead Sciences
- Cytovene · Roche Palo
GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication. - Foscavir · Clinigen Hlthcare
Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA. - Vistide · Gustave Roussy, Cancer Campus, Grand Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- CMV Retinitis in AIDS Patients patent landscape — cliff calendar, originator estates, attackable patents
- CMV Retinitis in AIDS Patients treatment landscape brief
- CMV Retinitis in AIDS Patients treatment updates RSS
Frequently asked questions about CMV Retinitis in AIDS Patients
What drugs treat CMV Retinitis in AIDS Patients?
Tracked treatments include Valcyte, Vistide, Cytovene, Foscavir.
What is the treatment for CMV Retinitis in AIDS Patients?
Standard treatment for CMV Retinitis in AIDS Patients includes Valcyte, Vistide, Cytovene, Foscavir. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: CMV Retinitis in AIDS Patients patent cliff · CMV Retinitis in AIDS Patients CI report
- Treatment: Valcyte · Cheplapharm
- Treatment: Vistide · Gilead Sciences
- Treatment: Cytovene · Roche Palo
- Treatment: Foscavir · Clinigen Hlthcare
- Treatment: Vistide · Gustave Roussy, Cancer Campus, Grand Paris
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing